

Technology Appraisal Committee B Interests Register

Topic: Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]

Publication Date: TBC.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Will Sullivan	TAC Committee Member	Financial Interests	Through his salaried role, Will is part of the team working with Amgen's global team on a project concerning an in-development technology for obesity and related comorbidities. Will declared this when the lead team invitation was sent and was advised to process at that stage.	16/01/2026	It was agreed that Will Sullivan's declaration would not prevent him from participating in discussions on this appraisal.
David McAllister	TAC Committee Member	Non-Financial Professional & Personal Interests	BI and UCB - use individual-level trial data provided by both sponsors via the Vivli platform in my academic research.	23/01/2026	It was agreed that David McAllister's declaration would not prevent him from participating in discussions on this appraisal.
Dr Toby Talbot	Clinical Expert	Direct – Financial	Previous paid activity with Amgen including speaker fees and travel grants, all over 2 years ago; no recent activity	31/01/2026	It was agreed that Dr Talbot' declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Thomas Newsom Davis	Clinical Expert	Direct – Financial	Abbvie, Accord, Amgen, Astra-Zeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, EQRx, Gilead, GSK, Johnson&Johnson, Lilly, Merck, MSD, Novartis, Novocure, Pfizer, Regeneron, Roche, Sanofi, Takeda	22/07/2025	It was agreed that Dr Davis' declaration would not prevent him from providing expert advice to the committee.
		Direct – non-financial	Independent Data Monitoring Committee for Roche & Clinical Trial Steering Committee for Astra Zeneca and MSD		